Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 7 of 7 clinical reviews.
A deep-dive into the enrollment biases, generalizability gaps, statistical caveats, and conflict-of-interest issues in the STEP-3 semaglutide 2.4 mg + intensive behavioral therapy trial.
Read clinical reviewA detailed methodology breakdown of the STEP-3 trial (semaglutide 2.4 mg + intensive behavioral therapy), covering randomization, blinding, estimand framework, inclusion criteria, and how each design choice shapes clinical interpretation.
Read clinical reviewHealth-economic analysis of semaglutide 2.4 mg plus intensive behavioral therapy from the STEP-3 trial: cost per QALY, payer coverage trends, list-price vs net-price realities, and individual value calculations.
Read clinical reviewDeep-dive into STEP-3 follow-up and extension findings for semaglutide 2.4 mg plus intensive behavioral therapy, covering weight regain after discontinuation, durability signals, and long-term safety.
Read clinical reviewComplete breakdown of the STEP-3 trial's primary and secondary endpoints for semaglutide 2.4 mg plus intensive behavioral therapy, including effect sizes, confidence intervals, response distribution, and time-course data.
Read clinical reviewDeep dive into STEP-3 pre-specified and post-hoc subgroup analyses for semaglutide 2.4 mg plus intensive behavioral therapy, examining differential responses by age, sex, BMI, race, and baseline cardiometabolic markers.
Read clinical reviewHow the STEP-3 trial of semaglutide 2.4 mg plus intensive behavioral therapy reshapes prescribing decisions, guideline recommendations, and real-world obesity management protocols.
Read clinical review